FDA-cleared profile

AI Platform 2.0 (AIP002)

Exo Imaging · Ultrasound · FDA-cleared (510(k))

Authorized purpose: Non-invasive processing of adult ultrasound for cardiac measurements including LVEF, wall thickness, and IVC diameter, plus lung and cardiac image-quality feedback in patients with suspected disease.

Clinical role
Real-time acquisition-quality feedback and measurement support; the algorithm/API modules are intended as accessories integrated by a programmer into a legally marketed ultrasound imaging device, while clinicians remain responsible for interpretation and management.
Images and patients
Ultrasound · Heart and lungs
Key limitation
Keep in mind: The device is for adults and patient-management decisions must not rely solely on its analysis. Certified healthcare professionals must review the data and ensure scan quality and diagnostic appropriateness. The packet establishes module-specific validation, not a single performance result for every possible ultrasound use.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Non-invasive processing of adult ultrasound for cardiac measurements including LVEF, wall thickness, and IVC diameter, plus lung and cardiac image-quality feedback in patients with suspected disease.
  • Which images or clinical context are in scope?Modality: Ultrasound Anatomy or clinical context: Heart and lungs Input: Single- and multi-frame DICOM ultrasound images from scanners within the specified compatibility range, including apical four-chamber and parasternal long-axis cardiac views and lung scans.
  • Who uses it?Intended users: Qualified healthcare professionals trained to conduct echocardiography and lung ultrasound scans; certified healthcare professionals interpret the data and remain responsible for scan quality and diagnosis.
  • What does the software produce?Output: Lung A-line and B-line presence or count and per-frame or per-clip quality scores; cardiac LVEF, interventricular-septum and posterior-wall thickness from the PLAX view, IVC minimum diameter on inspiration, IVC maximum diameter on expiration, and cardiac quality scores.
  • What is its most important limitation?Key limitation: The device is for adults and patient-management decisions must not rely solely on its analysis. Certified healthcare professionals must review the data and ensure scan quality and diagnostic appropriateness. The packet establishes module-specific validation, not a single performance result for every possible ultrasound use.

Clinical takeaway. Clinical role: Non-invasive processing of adult ultrasound for cardiac measurements including LVEF, wall thickness, and IVC diameter, plus lung and cardiac image-quality feedback in patients with suspected disease.

Evidence takeaway. Evidence from the reviewed source record: FDA validation evaluated left-ventricular wall thickness and IVC measurements in 100 subjects each against the average of three experts: ICC 0.93 for IVSd (95% CI 0.89-0.96), 0.94 for PWd (0.89-0.97), 0.93 for IVC minimum diameter (0.90-0.95), and 0.94 for IVC maximum diameter (0.90-0.96). Quality AI used 184 patients, 226 clips, and 29,732 frames, with ICC 0.94 for frames (95% CI 0.94-0.95) and clips (0.92-0.95). In real-time testing, 396 scans were performed by 26 users, including 18 novices with two hours of training; 98.3% and 98.0% were conditional agreement proportions against expert quality ratings.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Non-invasive processing of adult ultrasound for cardiac measurements including LVEF, wall thickness, and IVC diameter, plus lung and cardiac image-quality feedback in patients with suspected disease.
  • Exact FDA submission
  • Checked 2026-09-08
Workflow role
Real-time acquisition-quality feedback and measurement support; the algorithm/API modules are intended as accessories integrated by a programmer into a legally marketed ultrasound imaging device, while clinicians remain responsible for interpretation and management.
  • Exact FDA submission
  • Checked 2026-09-08
Required input
Single- and multi-frame DICOM ultrasound images from scanners within the specified compatibility range, including apical four-chamber and parasternal long-axis cardiac views and lung scans.
  • Exact FDA submission
  • Checked 2026-09-08
Output and clinician action
Lung A-line and B-line presence or count and per-frame or per-clip quality scores; cardiac LVEF, interventricular-septum and posterior-wall thickness from the PLAX view, IVC minimum diameter on inspiration, IVC maximum diameter on expiration, and cardiac quality scores.
  • Exact FDA submission
  • Checked 2026-09-08
Care setting
Adult echocardiography and lung-ultrasound workflow, including point-of-care scanning described in the FDA validation data.
  • Exact FDA submission
  • Checked 2026-09-08
Intended users
Qualified healthcare professionals trained to conduct echocardiography and lung ultrasound scans; certified healthcare professionals interpret the data and remain responsible for scan quality and diagnosis.
  • Exact FDA submission
  • Checked 2026-09-08
Limitations
The device is for adults and patient-management decisions must not rely solely on its analysis. Certified healthcare professionals must review the data and ensure scan quality and diagnostic appropriateness. The packet establishes module-specific validation, not a single performance result for every possible ultrasound use.
  • Exact FDA submission
  • Checked 2026-09-08
Evidence summary
FDA validation evaluated left-ventricular wall thickness and IVC measurements in 100 subjects each against the average of three experts: ICC 0.93 for IVSd (95% CI 0.89-0.96), 0.94 for PWd (0.89-0.97), 0.93 for IVC minimum diameter (0.90-0.95), and 0.94 for IVC maximum diameter (0.90-0.96). Quality AI used 184 patients, 226 clips, and 29,732 frames, with ICC 0.94 for frames (95% CI 0.94-0.95) and clips (0.92-0.95). In real-time testing, 396 scans were performed by 26 users, including 18 novices with two hours of training; 98.3% and 98.0% were conditional agreement proportions against expert quality ratings.
  • Exact FDA submission
  • Checked 2026-09-08

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA validation evaluated left-ventricular wall thickness and IVC measurements in 100 subjects each against the average of three experts: ICC 0.93 for IVSd (95% CI 0.89-0.96), 0.94 for PWd (0.89-0.97), 0.93 for IVC minimum diameter (0.90-0.95), and 0.94 for IVC maximum diameter (0.90-0.96). Quality AI used 184 patients, 226 clips, and 29,732 frames, with ICC 0.94 for frames (95% CI 0.94-0.95) and clips (0.92-0.95). In real-time testing, 396 scans were performed by 26 users, including 18 novices with two hours of training; 98.3% and 98.0% were conditional agreement proportions against expert quality ratings.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

AI Platform 2.0 (AIP002) regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K240953
  • Samplen=184
  • IndependenceIndependence not established

K240953

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K240953. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-08
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Single- and multi-frame DICOM ultrasound images from scanners within the specified compatibility range, including apical four-chamber and parasternal long-axis cardiac views and lung scans.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-08 · FDA K240953: AI Platform 2.0 (AIP002)

  2. Routing

    Source context, not route validation: Accepts DICOM data from ultrasound scanners in the specified range; the AI algorithm and API modules are intended to be integrated by another programmer into a legally marketed ultrasound imaging device. Exact local interfaces and versions are not established.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-08 · FDA K240953: AI Platform 2.0 (AIP002)

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-08 ·

  4. Returned objects

    Source context, not route validation: Lung A-line and B-line presence or count and per-frame or per-clip quality scores; cardiac LVEF, interventricular-septum and posterior-wall thickness from the PLAX view, IVC minimum diameter on inspiration, IVC maximum diameter on expiration, and cardiac quality scores.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-08 · FDA K240953: AI Platform 2.0 (AIP002)

  5. Viewer/worklist/report

    Unresolved route: Lung A-line and B-line presence or count and per-frame or per-clip quality scores; cardiac LVEF, interventricular-septum and posterior-wall thickness from the PLAX view, IVC minimum diameter on inspiration, IVC maximum diameter on expiration, and cardiac quality scores.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-08 · FDA K240953: AI Platform 2.0 (AIP002)

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Accepts DICOM data from ultrasound scanners in the specified range; the AI algorithm and API modules are intended to be integrated by another programmer into a legally marketed ultrasound imaging device. Exact local interfaces and versions are not established.
  • Exact FDA submission
  • Checked 2026-09-08
Security
Exo's Security Trust Center describes a company-wide security program for its cloud and mobile applications: information security policies based on ISO/IEC 27001, software development lifecycle security practices covering the platform and all applications, ongoing penetration testing of cloud services and applications, continuous monitoring with incident response, and business continuity plans validated by third-party audits (SOC 2, HITRUST, ISO 27001).
  • Vendor-wide
  • Checked 2026-10-27

Vendor statements; no certificates or audit reports read. Exo's dated HITRUST/SOC 2 certification announcement is scoped to the Exo Works workflow product specifically. Applicant 'Exo Imaging' bridges to Exo (exo.inc). Exact-release scope is not established.

Monitoring
Exo's security trust center states ongoing penetration testing, continuous monitoring and incident response across its platform and applications, with business continuity validated by third-party audits.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement, not an attestation. The page names Exo generally and does not scope these practices to any specific product release; exact-release scope is not established. Audit reports were not read.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for AI Platform 2.0 (AIP002); FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-08
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K240953
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Ultrasound
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Anatomy
Heart and lungs
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-08
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-08-05
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
21Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission

    No public price or quote for the exact K240953 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Deployment: Not verified - checked 2026-09-08 - Exact FDA submission

    The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-08 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K240953: AI Platform 2.0 (AIP002)

    U.S. Food and Drug Administration - Published 2024-08-05 - Accessed 2026-09-08

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. AI Platform 2.0 (AIP002) model card (K240953)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K240953

    U.S. Food and Drug Administration - Accessed 2026-09-08

    Scope: postmarketSafety

  8. Exo: Security Trust Center - Security

    Exo - Accessed 2026-10-27

    Scope: security

Research history

  1. K240953 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253535

Ligence Heart

Ligence Uab

Ligence Heart is a fully automated software platform that processes, analyses and makes measurements on acquired transthoracic cardiac ultrasound images, automatically producing a full report with measurements of several key cardiac structural and functional parameters. The data produced by this software is intended to be used to support qualified cardiologists or sonographers for clinical decision making. Ligence Heart is indicated for use in adult patients. Ligence Heart has not been validated for the assessment of congenital heart disease, valve disease, pericardial disease, and/or intra-cardiac lesions (e.g., tumors, thrombi). Limitations: Poor image capture will lead to poor annotations and subsequent measurements. Multiple image quality algorithms are used to filter out images of poor quality. Our software complements good patient care and does not exempt the user from the responsibility to provide supervision, clinically review the patient, and make appropriate clinical decisions. If no gender is present, female referenced guideline values will be used for conclusions. If Body Surface Area (BSA) is not present, indexed values cannot be provided. During image acquisition, inappropriate use of the echo machine, use of non-cardiac ultrasound probes, or use of suboptimal settings (e.g., gain, contrast, depth) may lead to lower accuracy of the software. Ligence Heart has not been validated in patients with prosthetic or surgically altered cardiac valves, implantable intracardiac devices, or irregular (non-sinus) rhythm; these conditions may affect automated measurement accuracy.

Modality
Ultrasound
Anatomy
Heart/Cardiovascular
Decision
2026-02-27
FDA-cleared K252235

PVAD IQ Software

Ultrasight, Ltd.

Authorized purpose: PVAD IQ supports qualified-physician clinical decision support by identifying the aortic annulus and PVAD inlet, calculating their mean distance, and identifying clips acceptable for this measurement.

Modality
Ultrasound
Anatomy
Heart/Cardiovascular
Decision
2025-12-18

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history